1**RESIST ACINETO test for the rapid detection of NDM and OXA acquired carbapenemases**2directly from blood culture in *Acinetobacter* species

3

Anaïs Potron^{1,2#}, Marion Daniel^{3#}, Mila Bay¹, Pauline Choulet¹, Thomas Garrigos^{3,4}, Loïk
 Sababadichetty³, Olivier Belmonte⁴, Damien Fournier¹, Katy Jeannot^{1,2#} and Guillaume Miltgen^{3,4,5#}.

6

1 Laboratoire Associé au Centre National de Référence de la Résistance aux Antibiotiques, Centre
Hospitalier Universitaire de Besançon, F-25000 Besançon, France.

9 2 Université de Franche-Comté, CNRS, UMR 6249 Chrono-environnement, F-25000 Besançon, France.

3 UMR Processus Infectieux en Milieu Insulaire Tropical, CNRS 9192, INSERM U1187, IRD 249,
Université de La Réunion, 97490, Saint-Clotilde, La Réunion, France.

4 Laboratoire de Bactériologie, Centre Hospitalier Universitaire de La Réunion, site Félix Guyon,
97400, Saint-Denis, La Réunion, France.

- 5 Centre Régional en Antibiothérapie de La Réunion (CRAtb Réunion), Saint-Pierre, La Réunion,
 France.
- [#] These authors contributed equally to the study.
- 17
- 18
- 19 * Corresponding author:
- 20 Guillaume Miltgen:
- e-mail address: guillaume.miltgen@chu-reunion.fr ; phone number: +262 6 92 36 96 57
- 22 postal address: Laboratoire de Bactériologie, CHU Félix Guyon, Allée des Topazes, 97400 Saint-Denis,
- 23 La Réunion, France
- 24
- 25 Running title: Rapid detection of carbapenemases in Acinetobacter sp

26

- 27
- 28 Keywords
- 29 *Acinetobacter*, carbapenemases, OXA-23, OXA-24/40, OXA-58, NDM, rapid detection, blood culture.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

30 Abstract

31

The immunochromatographic assay RESIST ACINETO (Coris BioConcept) was evaluated on a collection of 121 *Acinetobacter* spp. clinical isolates, including 104 carbapenemase producers. The strains producing carbapenemases OXA-23, -40, -58, or/and NDM were accurately detected from bacterial cultures and directly from blood cultures, with the exception of an OXA-23/NDM-1-positive *A. radioresistens* isolate (only detected through standard culture). The performance of the RESIST ACINETO test was excellent (sensitivity 99%, specificity 100%) on this collection of isolates.

38 Carbapenem-resistant Acinetobacter baumannii (CRAB) poses a significant global threat, 39 leading to a high mortality rate associated with antimicrobial resistance (1). This multidrug- or 40 extensively drug-resistant pathogen is identified by the WHO as one of the three critical priority 41 bacteria requiring urgent development of new antibiotics (2). In Acinetobacter species, the major 42 mechanism for carbapenem resistance is attributed to the production of carbapenem-hydrolysing 43 class D beta-lactamases, including OXA-23, OXA-24/40, and OXA-58 groups (3). Additionally, emerging NDM class B metallo-beta-lactamases play a significant role in conferring resistance (4,5). 44 45 Since the activity of the last-line antibiotics, such as the newly developed cefiderocol, depend on the 46 type of carbapenemase, rapid detection of these carbapenemase-producing bacteria has become 47 crucial for optimizing antibiotherapy in case of infection and implementing appropriate hygiene 48 measures (6). In recent years, several rapid immunochromatographic tests (Coris BioConcept, NG 49 Biotech) have been developed for the detection of carbapenemase-producing Enterobacterales ; but 50 none has been specifically designed for non-fermenting Gram-negative bacilli, with the exception of 51 the Coris OXA-23 K-SET test (accurate detection of OXA-23 group carbapenemases) (7–9). The novel 52 RESIST ACINETO test (Coris BioConcept) has recently been developed to detect the main 53 carbapenemases identified in the Acinetobacter species, namely the OXA-23-, OXA-24/40-, OXA-58-54 and NDM-groups (10). Here, we evaluated the performance of this novel immunochromatographic 55 assay for the detection of carbapenemase-producing Acinetobacter spp. encountered in mainland 56 and overseas France, from standard and blood cultures.

A large collection of 121 well-characterised *Acinetobacter* spp. clinical strains were selected from the French National Reference Center for Antibiotic Resistance (FNRC-AR) (*n*=61) and the University hospital of Reunion Island (*n*=60). The isolates were identified to the species level using matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometry (MALDI Biotyper; Bruker Daltonics) or by sequencing. The collection included 107 isolates of *A. baumannii calcoaceticus* complex (*A. baumannii n*=95, *A. pittii n*=10, *A. nosocomialis n*=2), 7 *A. ursingii*, 1 *A. haemolyticus*, 1 *A. johnsonii*, 1 *A. junii*, 1 *A. proteolyticus*, 1 *A. radioresistens*, 1 *A. townerii* and 1 *A. variabilis.* One hundred and four strains produced one (*n*=75) or two carbapenemases (*n*=29)
including 97 enzymes targeted by the test (27 OXA-23 type, 14 OXA-24/40 type, 6 OXA-58 type, 21
NDM type, 16 OXA-23+NDM-1, 3 OXA-58+NDM-1 and 10 others carbapenemase combinations)
(Table S1). Three non-targeted carbapenemase, IMP-63 (*n*=1) et VIM-4 (*n*=2), were included, as well
as 4 carbapenemase-hydrolyzing class D beta-lactamases (CHDL) rarely identified, OXA-235 (*n*=1),
OXA-255 (*n*=2) and OXA-679 (*n*=1) (Table 1).

70 The performance of the RESIST ACINETO test was evaluated according to the manufacturer's 71 recommendations from standard and blood cultures. From bacterial colonies, a 1 µL full calibrated 72 loop of bacteria grown for 16-24h at 35+/-2°C on Mueller-Hinton agar plate (bioMérieux) was added 73 to 6 drops of lysis buffer. After homogenisation, 100 μ l of the solution was added to the cassette. 74 From blood culture, a blood culture vial (BACTEC Plus Aerobic/F, Becton Dickinson) was inoculated with 1 mL of a bacterial suspension calibrated at 10² UFC/mL and incubated. Then, 1mL of the 75 76 positive blood culture was collected and treated with the RESIST-BC protocol, as recommended by 77 the manufacturer (Figure S1). Finally, 100 μ L of the extraction solution was transferred into the cassette. The reading of cassettes was performed by two operators in a double-blind after 15 min. 78 79 The sensitivity and specificity of the tests were calculated using the online program of the 80 VassarStats website (http://vassarstats.net).

81 For the 97 carbapenemase-producing strains targeted by the test, all enzymes were correctly 82 detected from standard and blood cultures, except for the A. radioresistens isolate (OXA-23 + NDM-83 1), where both enzymes were only detected from the standard culture (Table 1). However, 84 carbapenem resistant A. radioresistens isolates are very rare, representing less than 0.1% of 85 Acinetobacter species received at the FNRC-AR between 2013 and 2023. Seven NDM-producing strains have a low intensity band particularly from blood culture, with no inter-operator discordance 86 87 and was considered positive according to the manufacturer's recommendations (Figure 1). 88 Interestingly, the test detected in both growth conditions, the strains producing the OXA-255 (n=2)89 and OXA-679 (n=1) enzymes, which share 87% and 73% amino acid identity with OXA-24/40,

90 respectively (these strains were considered true positives for the performance calculation) (15). 91 However, the test failed to detect the OXA-235 enzyme, which shares an amino acid identity lower 92 than 65% with the enzymes OXA-24/40 (59%), OXA-23 (61%), and OXA-58 (64%). No false positives 93 were observed for the strains producing a non-targeted carbapenemase (IMP-63 and VIM-4) or other 94 beta-lactamases (CTX-M-, GES-, PER-, CARB-, RTG-, TEM-types) (Table 1). The test exhibited a 95 sensitivity of 100% in standard cultures and 99% in blood cultures, while demonstrating a specificity of 100% in both conditions. Thus, the RESIST ACINETO test proves to be a reliable method for 96 97 detecting carbapenemases in Acinetobacter species, as demonstrated by two recent studies (10,11) 98 focusing on standard cultures. In our study, we extended the evaluation to blood culture, revealing 99 consistent results with the previous findings.

100 These results opens up new potential applications for the test based on blood cultures (11). 101 The use of the RESIST ACINETO test could prove highly beneficial for countries with a high frequency 102 of carbapenem-resistant Acinetobacter species isolates, particularly in cases where the A. baumannii-103 calcoaceticus complex is responsible for a significant proportion of healthcare-associated bacteremia 104 (e.g. South East Asia and the Balkans) (12,13). When performed directly after the presumptive 105 identification of Gram-negative (coco-)bacilli in a positive blood culture, this test could facilitate the 106 early detection imipenem-resistant isolates. It may also enable the optimization of treatment based 107 on the type of carbapenemase present. It is well established that the MIC of cefiderocol against 108 NDM-producing A. baumannii isolates are typically higher than 2 mg/L (6). This test could further 109 assist in directing treatment towards alternative therapeutic options.

110 In conclusion, the RESIST ACINETO test is a rapid, easy-to-use, and cost-effective test that 111 demonstrates excellent performance in detecting the major acquired carbapenemases present in the 112 *Acinetobacter* species. It has the potential to be considered as an option for routine use in 113 microbiology laboratories.

114 Acknowledgments

115

- 116 This work was partially supported by the French Ministry of Health via Santé Publique France, and
- the ERDF European program (RESISTO-RUN project, 20201126-0022906).
- 118 We would also like to thank Coris BioConcept for supplying the kits. We precise Coris BioConcept was
- not involved in the design of the study or analysis of the results.

120

121

122 References

- 123 1. Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 124 2019: a systematic analysis. Lancet. 2022 Feb 12;399(10325):629–55.
- WHO publishes list of bacteria for which new antibiotics are urgently needed [Internet]. Available
 from: https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new antibiotics-are-urgently-needed.
- Potron A, Poirel L, Nordmann P. Emerging broad-spectrum resistance in *Pseudomonas aeruginosa* and *Acinetobacter baumannii*: Mechanisms and epidemiology. Int J Antimicrob Agents. 2015 Jun;45(6):568–85.
- Nordmann P, Poirel L. Epidemiology and diagnostics of carbapenem resistance in Gram-negative
 bacteria. Clin Infect Dis. 2019 Nov 13;69(Suppl 7):S521–8.
- Hsu LY, Apisarnthanarak A, Khan E, Suwantarat N, Ghafur A, Tambyah PA. Carbapenem-resistant
 Acinetobacter baumannii and *Enterobacteriaceae* in South and Southeast Asia. Clin Microbiol Rev.
 2017 Jan;30(1):1–22.
- 6. Karakonstantis S, Rousaki M, Vassilopoulou L, Kritsotakis El. Global prevalence of cefiderocol nonsusceptibility in Enterobacterales, *Pseudomonas aeruginosa, Acinetobacter baumannii* and *Stenotrophomonas maltophilia*: a systematic review and meta-analysis. Clin Microbiol Infect. 2023 Sep 2;S1198-743X(23)00413-5.
- Rösner S, Kamalanabhaiah S, Küsters U, Kolbert M, Pfennigwerth N, Mack D. Evaluation of a novel immunochromatographic lateral flow assay for rapid detection of OXA-48, NDM, KPC and VIM carbapenemases in multidrug-resistant *Enterobacteriaceae*. J Med Microbiol. 2019 Mar;68(3):379–81.
- 8. Bernabeu S, Bonnin RA, Dortet L. Comparison of three lateral flow immunochromatographic
 assays for the rapid detection of KPC, NDM, IMP, VIM and OXA-48 carbapenemases in
 Enterobacterales. J Antimicrob Chemother. 2022 Oct 28;77(11):3198–205.
- 9. Fournier D, Triponney P, Gabriel L, Plésiat P, Jeannot K, Potron A. Evaluation of 5 rapid colorimetric and immunochromatographic tests for the detection of carbapenemases in *Pseudomonas aeruginosa* and *Acinetobacter* spp. isolates. Eur J Clin Microbiol Infect Dis. 2023 Aug;42(8):1043–5.
- Mertins S, Higgins PG, Thunissen C, Magein H, Gilleman Q, Mertens P, González Rodríguez M,
 Maus LM, Seifert H, Krönke M, Klimka A. Development of an immunochromatographic lateral flow
 assay to rapidly detect OXA-23-, OXA-40-, OXA-58- and NDM-mediated carbapenem resistance
 determinants in *Acinetobacter baumannii*. J Med Microbiol. 2023 Apr;72(4).
- 11. Bouvier M, Kerbol A, Findlay J, Freire S, Poirel L, Nordmann P. Resist Acineto rapid immunological
 test for the detection of acquired carbapenemase producers among *Acinetobacter* spp. Diagn
 Microbiol Infect Dis. 2023 Aug 9;107(3):116043.
- 12. Healthcare-associated infections acquired in intensive care units. Annual Epidemiological Report
 for 2019. ECDC, 2023 May. [Internet]. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/healthcare-associated-infectionsintensive-care-units-annual-epidemiological-report-2019.pdf

13. Gajic I, Jovicevic M, Popadic V, Trudic A, Kabic J, Kekic D, Ilic A, Klasnja S, Hadnadjev M, Popadic
 DJ, Andrijevic A, Prokic A, Tomasevic R, Ranin L, Todorovic Z, Zdravkovic M, Opavski N. The
 emergence of multi-drug-resistant bacteria causing healthcare-associated infections in COVID-19
 patients: a retrospective multi-centre study. J Hosp Infect. 2023 Jul;137:1–7.

14. Miltgen G, Bour M, Allyn J, Allou N, Vedani T, Vuillemenot JB, Triponney P, Martinet O, Lugagne
N, Benoit-Cattin T, Dortet L, Birer A, Jaffar-Bandjee M-C, Belmonte O, Plésiat P, Potron A. Molecular
and epidemiological investigation of a colistin-resistant OXA-23-/NDM-1-producing *Acinetobacter baumannii* outbreak in the Southwest Indian Ocean Area. Int J Antimicrob Agents. 2021
Oct;58(4):106402.

15. Tietgen M, Kramer JS, Brunst S, Djahanschiri B, Wohra S, Higgins PG, Weidensdorfer M, Riedel Christ S, Pos KM, Gonzaga A, Steglich M, Nübel U, Ebersberger I, Proschak E, Göttig S. Identification of
 the novel class D β-lactamase OXA-679 involved in carbapenem resistance in *Acinetobacter calcoaceticus*. J Antimicrob Chemother. 2019 Jun 1;74(6):1494–502.

175

176

177

178 Appendices

179 Figure's legend

- 180 Figure 1. Representation of RESIST ACINETO test results for some isolates of interest.
- 181
- 182 Table's legend
- 183 Table 1. Coris ACINETO results obtained with bacterial and blood cultures on the 121 isolates tested.
- 184 P: positive; N: negative.

185

186 Supplemental material

187

Figure S1: Blood culture sample processing protocol (adapted from RESIST-BC protocol, Coris
 BioConcept, technical note n°IFU-57S01/FR/V02, <u>https://www.corisbio.com/products/resist-acineto</u>).

190

191 Table S1: Molecular characteristics of the 121 *Acinetobacter* spp. isolates included in the study.

Strains originating in mainland France are marked as "France", strains originating in overseas territories are marked with a distinctive sign ([#] Guadeloupe, ⁺ Guyane, [#] Mayotte, * Reunion). The 4 light grey lines correspond to the rare oxacillinase variants (OXA-235, OXA-255, OXA-679) tested. The dark grey line corresponds to the *A. radioresistens* OXA-23+NDM-1 strain not detected in blood culture.

197

Figure 1. Representation of RESIST ACINETO test results for some isolates of interest.



Table 1. Coris ACINETO results obtained with bacterial and blood cultures on the 121 isolates tested.

Category	Species	Resistance mechanism	Number of strains	Coris ACINETO results obtained with bacterial culture			% Sensitivity (95% CI)	% Specificity (95% CI)	Coris ACINETO results obtained with blood culture			% Sensitivity (95% CI)	% Specificity (95% CI)
				OXA-40/58	OXA-23	NDM	76 Sensitivity (55% Ci)	/ Specificity (55% ci)	OXA-40/58	OXA-23	NDM	/ sanaturey (55/6 Cl)	76 Specificity (5576 Ci)
OXA-23 type (n = 27)	Acinetobacter spp.	OXA-23	25	N	Р	N	100 (88-100)	100 (88-100)	N	Р	N	100 (88-100)	100 (88-100)
	Acinetobacter spp.	OXA-565	2	N	Р	N			N	Р	N		
OXA-24/40 type (n =14)	Acinetobacter baumannii	OXA-24	5	Р	N	N	100 (78-100)	100 (78-100)	Р	N	N	100 (78-100)	100 (78-100)
	Acinetobacter baumannii	OXA-72	9	Р	N	N			Р	N	N		
OXA-58 type (n =6)	Acinetobacter baumannii	OXA-58	3	Р	N	N	100 (61-100)	100 (61-100)	Р	N	N	100 (61-100)	100 (61-100)
	Acinetobacter spp.	OXA-420	3	Р	N	N			Р	N	N		
NDM-type (n =21)	Acinetobacter spp.	NDM-1	20	N	N	Р	100 (84-100)	100 (84-100)	N	N	Р	100 (84-100)	100 (84-100)
	Acinetobacter baumannii	NDM-9	1	N	N	Р			N	N	Р		
Multiples carbapenemase producers (n = 29)	Acinetobacter baumannii	OXA-23 + OXA-58	3	Р	Р	N			Р	Р	N		
	Acinetobacter baumannii	OXA-23 + OXA-420	3	Р	P	N			Р	Р	N		
	Acinetobacter baumannii	NDM-1 + OXA-23	15	N	P	Р			N	Р	Р		
	Acinetobacter radioresistens	NDM-1 + OXA-23	1	N	Р	Р			N	N	N		
	Acinetobacter baumannii	NDM-1 + OXA-24	1	Р	N	Р			Р	N	Р		
	Acinetobacter spp.	NDM-1 + OXA-58	3	Р	N	Р			Р	N	Р		
	Acinetobacter baumannii	NDM-1 + OXA-420	1	P	N	Р			Р	N	Р		
	Acinetobacter baumannii	NDM-5 + OXA-23	1	N	Р	Р			N	Р	Р		
	Acinetobacter junii	IMP-37 + OXA-58	1	Р	N	N			Р	N	N		
Other carbapenemase producers (n =7)	Acinetobacter baumannii	OXA-235	1	N	N	N			N	N	N		
	Acinetobacter pittii	OXA-255	2	Р	N	N			Р	N	N		
	Acinetobacter pittii	OXA-679	1	Р	N	N			Р	N	N		
	Acinetobacter baumannii	IMP-63	1	N	N	N			N	N	N		
	Acinetobacter spp.	VIM-4	2	N	N	N			N	N	N		
Non-carbapenemase producers (n =17)	Acinetobacter baumannii	Wild type	1	N	N	N			N	N	N		
	Acinetobacter baumannii	Overexpressed cephalosporinase	5	N	N	N			N	N	N		
	Acinetobacter baumannii	Overproduction of efflux pumps	2	N	N	N			N	N	N		
	Acinetobacter baumannii	CTX-M-15 + CARB-2	1	N	N	N			N	N	N		
	Acinetobacter baumannii	GES-11	1	N	N	N			N	N	N		
	Acinetobacter baumannii	PER-1	1	N	N	N			N	N	N		
	Acinetobacter baumannii	CARB-5	2	N	N	N			N	N	N		
	Acinetobacter baumannii	SHV-12 + CTX-M-15	1	N	N	N			N	N	N		
	Acinetobacter baumannii	TEM-1	2	N	N	N			N	N	N		
	Acinetobacter johnsonii	Wild type	1	N	N	N			N	N	N		